AMENDMENTS

In the Claims:

Please amend claims 69-72, 74 and 75 as follows.

Please add new claims 79-81 as follows.

69. (Amended) A pharmaceutical composition that induces tolerance to an antigen, said composition comprising a non-tumor lymphoid cell or non-tumor hematopoietic cell suitable for introduction into an individual and a pharmaceutically acceptable excipient, wherein said cell contains a nucleic acid sequence encoding a fusion protein operably linked to a promoter,

91.

said fusion protein comprising (1) an immunoglobulin heavy chain or light chain; and (2) a polypeptide containing at least one epitope of the antigen;

wherein upon introduction to the individual said composition induces tolerance to the antigen in the individual.

70. (Amended) The pharmaceutical composition of claim 69, wherein said nucleic acid sequence was introduced into the cell in a viral vector.

71. (Amended) The pharmaceutical composition of claim 70, wherein said viral vector is selected from the group consisting of retroviral vector, and baculovirus vector.

72. (Amended) The pharmaceutical composition of claim 70, wherein there are two or more copies of the nucleic acid sequence encoding said fusion protein of claim 69 operatively linked to said promoter.

74. (Amended) The pharmaceutical composition of claim 70, wherein said fusion protein comprises an N-terminal variable region of said heavy chain and has said polypeptide inserted adjacent to the first framework region of said N-terminal variable region.

92

75. (Amended) The pharmaceutical composition of claim 70, wherein the nucleic acid sequence is introduced by a virus encoding the fusion protein.

79. (New) The composition of claim 69, wherein the cell is a hematopoietic cell.

93 80. (New) The composition of claim 69 wherein the antigen is an autoimmune antigen.

81. (New) The composition of claim 69 wherein the antigen is an allergan.